November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting stent (DES) from Medtronic Inc. continues to demonstrate consistently positive performance across a variety of studies. These conclusions come from two new data analyses being presented this week at Transcatheter Cardiovascular Therapeutics (TCT) 2011.

November 9, 2011 – Abiomed, a provider of heart support technologies, announced results of an economic study at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) conference. The economic study demonstrated that Impella significantly reduced major adverse events at an incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies.  Quality of life benefits included an increase in ejection fraction of over 20 percent and an improvement in New York Heart Association (NYHA) Class III and Class IV heart failure of over 50 percent.

November 9, 2011 – Siemens Healthcare announced that the company has entered into a definitive agreement to acquire all issued and outstanding equity of MobileMD Inc., of Yardley, Pa., a provider of health information exchange (HIE) solutions.